Ibuprofen
Ibuprofen
Contact Us

We are here to help in anything you need. Please use our online system or send an email to inquiry@alfa-chemistry.com.

Ibuprofen

Inquiry
Catalog Number PR15687271
CAS 15687-27-1
Structure
Description Ibuprofen is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of ibuprofen is as a Cyclooxygenase Inhibitor.
Synonyms Motrin; Brufen; Advil; Nurofen
IUPAC Name 2-[4-(2-methylpropyl)phenyl]propanoic acid
Molecular Weight 206.28
Molecular Formula C13H18O2
InChI HEFNNWSXXWATRW-UHFFFAOYSA-N
InChI Key InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)
Documentation/Certification FDA / CEP / EU GMP
Drug Categories Acids, Carbocyclic; Agents causing angioedema; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antiinflammatory Preparations, Non-Steroids for Topical Use; Antiinflammatory Products for Vaginal Administration; Antirheumatic Agents; Arylpropionic acid NSAIDS; Central Nervous System Agents; COX-1 Inhibitors; COX-2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Experimental Unapproved Treatments for COVID-19; Nephrotoxic agents; Nervous System; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OATP2B1/SLCO2B1 substrates; Other Nonsteroidal Anti-inflammatory Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; Pharmaceutical Preparations; Phenylpropionates; Propionates; Sensory System Agents; Throat Preparations; Topical Products for Joint and Muscular Pain; UDP Glucuronosyltransferases Inhibitors; UGT1A1 Substrates; UGT1A3 substrates; UGT1A9 Substrates; UGT2B17 Inhibitors; UGT2B7 substrates
Drug Interactions Abacavir-Ibuprofen may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abametapir-The serum concentration of Ibuprofen can be increased when it is combined with Abametapir.
Abatacept-The metabolism of Ibuprofen can be increased when combined with Abatacept.
Abciximab-The risk or severity of bleeding can be increased when Ibuprofen is combined with Abciximab.
Abiraterone-The metabolism of Ibuprofen can be decreased when combined with Abiraterone.
Isomeric SMILES CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
Type Small Molecule
Therapeutic Category Anti-Inflammatory Agents
Pharmacology

Indications

Ibuprofen, a widely used nonsteroidal anti-inflammatory drug (NSAID), serves multiple therapeutic purposes. It is commonly utilized as an analgesic, anti-inflammatory, and antipyretic. The racemic mixture of ibuprofen and its enantiomer, Dexibuprofen, is prescribed for managing mild to moderate pain associated with various conditions such as dysmenorrhea, headaches, migraines, postoperative dental pain, spondylitis, osteoarthritis, rheumatoid arthritis, and soft tissue disorders. Additionally, ibuprofen's ability to inhibit prostaglandin and thromboxane synthesis may affect platelet function and cause prolongation of gestation and labor. Its therapeutic indications extend to treating Patent Ductus Arteriosus, a neonatal condition where the ductus arteriosus fails to close post-birth, utilizing its prostaglandin-inhibiting properties. Moreover, ibuprofen is effective in alleviating symptoms of rheumatoid and osteoarthritis, and managing cystic fibrosis by reducing lung inflammation. It can also benefit patients with severe orthostatic hypotension through sodium retention. Furthermore, ibuprofen is employed in managing acute and chronic orofacial pain, reducing minor aches, fever, and as an adjunct to opioids for more severe pain. Investigational uses of ibuprofen include potential roles in the prophylaxis of Alzheimer's and Parkinson's diseases, as well as breast cancer prevention.

Pharmacodynamics

Ibuprofen exerts its effects through the inhibition of prostanoid synthesis by cyclooxygenase (COX) enzymes COX-1 and COX-2, which are involved in pain, fever, and inflammation pathways. Its analgesic activity is associated with both peripheral and central nervous system mechanisms, potentially involving enhanced synthesis of endogenous cannabinoids and interaction with NMDA receptors. The antipyretic effects of ibuprofen are attributed to the reduced synthesis of prostanoids, which are principal mediators of fever in the hypothalamic-preoptic area. In dental procedures, ibuprofen's efficacy is linked to inhibiting local prostanoid production, reducing edema, and increasing plasma beta-endorphins. It also displays effectiveness in controlling joint symptoms in rheumatic diseases and managing dysmenorrhea by significantly reducing menstrual prostanoids and uterine contractions. Additionally, ibuprofen reduces fever and pain caused by migraines, potentially due to effects on platelet activation and thromboxane A2 production. In investigational uses, low-dose ibuprofen has been shown to mitigate neurodegeneration, while its potential in Parkinson's disease is tied to combating inflammation and oxidative stress. Moreover, ibuprofen has been investigated for its possible role in decreasing breast cancer incidence.

Absorption

Following oral administration, ibuprofen is well-absorbed, reaching peak serum concentrations within 1 to 2 hours. While the rate of absorption may decrease slightly if taken immediately post-meal, the overall extent of absorption remains unaffected. In adults, ibuprofen is rapidly absorbed in the upper gastrointestinal tract, with average pharmacokinetic parameters ranging as follows: a maximum concentration (Cmax) of about 20 mcg/ml, a time to maximum concentration (Tmax) of approximately 2 hours, and an area under the curve (AUC) of approximately 70 mcg.h/ml. These values may vary based on the specific enantiomer form, dosing, and administration route.

Metabolism

Ibuprofen undergoes rapid hepatic metabolism through Phase I and Phase II metabolic pathways. Phase I involves hydroxylation of the isobutyl side chains leading to the creation of hydroxy and carboxy derivatives. This step is primarily facilitated by cytochrome P450 enzymes, notably CYP 2C9, CYP 2C19, and CYP 2C8, with CYP 2C9 being the major catalyst. The R-enantiomer of ibuprofen also undergoes substantial conversion (53-65%) to the more active S-enantiomer via alpha-methylacyl-CoA racemase. Following Phase I, oxidative metabolites undergo Phase II conjugation to form phenolic and acyl glucuronides before excretion.

Mechanism of Action

Ibuprofen functions as a non-steroidal anti-inflammatory drug (NSAID), acting as a non-selective inhibitor of the cyclooxygenase (COX) enzymes, COX-1 and COX-2. These enzymes play a crucial role in the arachidonic acid pathway, which is responsible for the synthesis of prostaglandins and thromboxanes. Prostaglandins are mediators of pain, fever, and inflammation, while thromboxanes are involved in blood clotting. By inhibiting COX-2, ibuprofen effectively reduces the production of prostaglandins, thereby alleviating inflammation, pain, fever, and swelling. However, the inhibition of COX-1 can lead to certain side effects, such as gastrointestinal ulceration. Despite extensive research, the precise mechanism through which ibuprofen exerts its effects remains not fully elucidated.

It should be noted that our service is only used for research, not for clinical use.

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

Accept Cookies
x